Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. The Organogenesis news feed highlights company announcements, clinical updates, financial results, and regulatory developments that help investors and healthcare professionals understand how the business is evolving.
News about Organogenesis frequently covers its regenerative medicine portfolio and its position in the skin substitutes and cellular and tissue-based products (CTP) market. The company issues press releases on quarterly and year-to-date financial performance, including net product revenue from Advanced Wound Care and Surgical & Sports Medicine products, net income or loss, and adjusted metrics such as adjusted net income and adjusted EBITDA. These updates often include management commentary on market conditions, reimbursement dynamics, and expectations for future periods.
A major theme in Organogenesis news is the development of ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis. The company publishes detailed updates on Phase 3 randomized controlled trials, including pain and function outcomes, safety observations, and plans for regulatory submissions. Announcements have described FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ReNu, plans for a Biologics License Application (BLA), and the initiation of a rolling BLA submission.
Additional news items include commentary on Centers for Medicare & Medicaid Services (CMS) payment reforms for skin substitutes/CTPs, participation in investor conferences, and corporate governance developments such as inducement equity grants and stockholder meeting results. By following this page, readers can review a chronological record of how Organogenesis communicates its financial performance, clinical progress, reimbursement environment, and corporate actions.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported a 10% decline in Q4 2022 net revenue, totaling $115.5 million, down from $127.9 million in Q4 2021. The decrease was attributed to a 10% drop in Advanced Wound Care product revenue. Net income fell sharply to $7.5 million, down from $51.0 million year-over-year. For 2022, net revenue was $450.9 million, down 4% from 2021, with net income declining 83% to $15.5 million. Looking ahead, the company expects 2023 net revenue to range between $450.0 million and $462.0 million, indicating flat growth. Organogenesis anticipates solid growth in the hospital outpatient setting while addressing challenges in the physician office environment.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has reported positive results from the interim analysis of its Phase 3 clinical trial for treating knee osteoarthritis symptoms. The analysis, conducted on 50% of the 474 patients enrolled, showed a favorable outcome, allowing the trial to proceed without modifications. The Independent Data Monitoring Committee indicated that safety data aligned with expectations for the ReNu treatment. This trial targets a significant health issue, affecting millions of Americans, and is crucial for patients with moderate to severe symptoms.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced it will release its fourth quarter and fiscal year 2022 financial results after market close on March 1, 2023. Management will hold a conference call at 5:00 p.m. ET on the same day to discuss the financial results and provide a corporate update, followed by a Q&A session. Investors can access the live webcast through the company’s website or via teleconference links provided in the announcement. Organogenesis specializes in regenerative medicine, particularly for advanced wound care and surgical markets, offering innovative product solutions to meet patient needs.
Organogenesis Holdings Inc. (Nasdaq: ORGO) will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology, and Medtech Conference on December 8, 2022. Held at The Fontainebleau Miami Beach, the event will feature panel discussions and 1x1 meetings with investors. This conference highlights the company’s focus on regenerative medicine, specifically in advanced wound care and surgical solutions. Organogenesis offers a range of bioactive and acellular biomaterials designed to meet diverse patient needs.
Organogenesis Holdings reported third quarter 2022 results with net revenue of $116.9 million, a 3% increase from $113.8 million in Q3 2021. Advanced Wound Care products generated $109.5 million (+2%), while Surgical & Sports Medicine products rose to $7.3 million (+15%). However, net income dropped to $0.2 million from $12.6 million, a significant decrease of $12.4 million. Adjusted net income also fell sharply to $5.1 million, down 68%. The company revised its full-year revenue guidance, anticipating a challenging Q4 due to competitive pressures and reimbursement uncertainties.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced that it will report its third quarter fiscal year 2022 financial results on November 9, 2022, after market closure. A conference call will follow at 5:00 p.m. ET on the same day, offering a corporate update and a Q&A session. Interested participants can access the call via a live webcast or teleconference, with an archived version available on the company’s website for one year. Organogenesis focuses on regenerative medicine solutions for advanced wound care and surgical markets.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference, taking place from September 12-14, 2022, at the Sheraton New York Times Square Hotel. The management will engage in a fireside chat on September 13 at 11:45 a.m. Eastern Time. A live audio webcast of the presentation will be available on the company’s website, with a replay accessible for 30 days post-conference. Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical solutions.
Organogenesis Receives FDA Clearance for PuraPly MZ
On August 15, 2022, Organogenesis announced the FDA clearance of PuraPly MZ, an innovative powdered product for complex surgical wounds. This marks a significant milestone as it expands their PuraPly portfolio into the surgical and sports medicine markets. PuraPly MZ utilizes native structured collagen to enhance healing in complex wounds, addressing a pressing need in the medical community, with estimates indicating that 28% of surgical sites in the U.S. require specific attention for effective healing.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q2 2022 net revenue of $121.4 million, down 1% year-over-year, with Advanced Wound Care up 2% to $113.8 million while Surgical & Sports Medicine fell 35% to $7.6 million. Net income decreased significantly by 58% to $8.7 million, or $0.07 per share. Adjusted EBITDA dropped to $18.6 million from $25.1 million a year ago. For FY 2022, the company projects revenue between $465 million and $490 million, reflecting a modest annual decline or growth.
Organogenesis Holdings Inc. (Nasdaq: ORGO) announced its second quarter fiscal year 2022 financial results will be released after market close on August 9, 2022. A conference call will follow at 5:00 p.m. Eastern Time, providing an overview of the results and corporate updates. Interested participants can access the live webcast through the company's investor relations website. The archived version will also be available for roughly one year. Organogenesis specializes in regenerative medicine, focusing on products for Advanced Wound Care and Surgical & Sports Medicine.